EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16

Yi Ru, Yue Ma-Lauer iD, Chengyu Xiang, Pengyuan Li, Brigitte von Brunn, Anja Richter, Christian Drosten, Andreas Pichlmair iD, Susanne Pfefferle iD, Markus Klein, Robert D Damoiseaux iD, Ulrich A K Betz iD und 1 weitere

Pathogens · 2025

DOI: 10.3390/pathogens14090871 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Yi Ru und 12 weiteren Autor:innen. Beteiligte Einrichtung: Max-von-Pettenkofer Institute, Virology Department, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany. Hauptthemen laut MEDLINE: SARS-CoV-2, Boron Compounds, Antiviral Agents, Glycine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Center for Infection Research (DZIF), Bundesministerium fuer Bildung und Forschung of the German Government, German Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of human coronaviruses has led to three epidemics or pandemics in the last two decades, collectively causing millions of deaths and thus highlighting a long-term need to identify new antiviral drug targets and develop antiviral therapeutics. In this study, a compound library was screened to uncover novel potential inhibitors of coronavirus replication. Three lead compounds, designated #16-14, #16-23, and #16-24, which were Ixazomib and its analogs, were identified based on their potent antiviral activity and minimal cytotoxicity. These compounds were found to inhibit the immunoproteasome subunit LMP7, a target whose subcellular localization and expression are altered in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-infected Huh7 cells. Yeast two-hybrid assays and co-immunoprecipitation further revealed that LMP7 interacts with the viral proteins Nsp13 and Nsp16. In addition, Nsp13 and Nsp16 disrupted the expression of LMP7 in response to pathogen attacks. Functional studies showed that LMP7 knockout in BEAS-2B-ACE2 cells resulted in enhanced replication of attenuated SARS-CoV-2, highlighting the role of this subunit in restricting viral replication. Taken together, these findings position LMP7 as a novel therapeutic target and highlight Ixazomib and its analogs as potential antiviral agents against current and future coronavirus threats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Boron CompoundsAntiviral AgentsGlycineCOVID-19 Drug TreatmentViral Nonstructural ProteinsProteasome Endopeptidase ComplexHumansVirus ReplicationCOVID-19

Stichwörter der Autor:innen

IxazomibLMP7Nsp13Nsp16SARS-CoV-2immunoproteasome

Substanzen

ixazomibBoron CompoundsAntiviral AgentsGlycineViral Nonstructural ProteinsProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Max-von-Pettenkofer Institute, Virology Department, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany.
  • German Center for Infection Research (DZIF), Munich Site, 80336 Munich, Germany.
  • Institute of Virology, Campus Charite' Mitte, Charite'-Universitätsmedizin Berlin, 10117 Berlin, Germany.
  • Institute of Virology, School of Medicine, Technical University of Munich, 80333 Munich, Germany.
  • Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Merck KGaA, 64293 Darmstadt, Germany.

ORCID-Profile: Yue Ma-Lauer, Andreas Pichlmair, Susanne Pfefferle, Robert D Damoiseaux, Ulrich A K Betz

Förderung

  • German Center for Infection Research (DZIF)
  • Bundesministerium fuer Bildung und Forschung of the German Government
  • German Government
  • Merck KGaA, Darmstadt, Germany

Zitieren

APA

Ru, Y., Ma-Lauer, Y., Xiang, C., Li, P., von Brunn, B., Richter, A., Drosten, C., Pichlmair, A., Pfefferle, S., Klein, M., Damoiseaux, R. D., Betz, U. A. K., & von Brunn, A. (2025). LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens. https://doi.org/10.3390/pathogens14090871

Vancouver

Ru Y, Ma-Lauer Y, Xiang C, Li P, von Brunn B, Richter A, et al. LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16. Pathogens. 2025. doi:10.3390/pathogens14090871

BibTeX
@article{Ru2025,
  author = {Ru, Yi and Ma-Lauer, Yue and Xiang, Chengyu and Li, Pengyuan and von Brunn, Brigitte and Richter, Anja and Drosten, Christian and Pichlmair, Andreas and Pfefferle, Susanne and Klein, Markus and Damoiseaux, Robert D and Betz, Ulrich A K and von Brunn, Albrecht},
  title = {LMP7 as a Target for Coronavirus Therapy: Inhibition by Ixazomib and Interaction with SARS-CoV-2 Proteins Nsp13 and Nsp16},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14090871}
}
Kostenlos starten →